$12.1B
acquisition price
Swedish private equity firm EQT has agreed to acquire the life-sciences and diagnostics provider Qiagen for €10.8 billion ($12.1 billion) in an all-cash deal.
22 Oct
Every figure reported in biotechnology news this week, with what each figure measures, when it was reported and where it was published.
500 figures were reported across 254 biotechnology articles in this window. The table lists the 60 carried by the highest-ranked articles.
Swedish private equity firm EQT has agreed to acquire the life-sciences and diagnostics provider Qiagen for €10.8 billion ($12.1 billion) in an all-cash deal.
22 Oct
Swedish private equity firm EQT has agreed to acquire the life-sciences and diagnostics provider Qiagen for €10.8 billion ($12.1 billion) in an all-cash deal.
22 Oct
Swedish private equity firm EQT has agreed to acquire the life-sciences and diagnostics provider Qiagen for €10.8 billion ($12.1 billion) in an all-cash deal.
22 Oct
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran (mRNA-4157), combined with Keytruda, reduced the risk of death or recurrence of melanoma by 42% compared to standard treatment.
22 Oct
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran (mRNA-4157), combined with Keytruda, reduced the risk of death or recurrence of melanoma by 42% compared to standard treatment.
22 Oct
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran (mRNA-4157), combined with Keytruda, reduced the risk of death or recurrence of melanoma by 42% compared to standard treatment.
22 Oct
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran (mRNA-4157), combined with Keytruda, reduced the risk of death or recurrence of melanoma by 42% compared to standard treatment.
22 Oct
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran (mRNA-4157), combined with Keytruda, reduced the risk of death or recurrence of melanoma by 42% compared to standard treatment.
22 Oct
Karl Deisseroth, Peter Hegemann, and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine for their pioneering research in optogenetics.
19 Oct
Merck KGaA has agreed to acquire Silence Therapeutics in a deal valued at $1.3 billion.
19 Oct
Texas-based startup Warhound has secured $200 million in funding to develop genetically enhanced military and police dogs equipped with Anduril's cybernetic technology.
23 Oct
Texas-based startup Warhound has secured $200 million in funding to develop genetically enhanced military and police dogs equipped with Anduril's cybernetic technology.
23 Oct
Moderna and Merck reported that their personalized mRNA vaccine, intismeran, reduced the risk of melanoma recurrence or death by 42% in a phase III clinical trial.
22 Oct (reported 23 Oct)
Moderna and Merck reported that their personalized mRNA vaccine, intismeran, reduced the risk of melanoma recurrence or death by 42% in a phase III clinical trial.
22 Oct (reported 23 Oct)
Moderna and Merck reported that their personalized mRNA vaccine, intismeran, reduced the risk of melanoma recurrence or death by 42% in a phase III clinical trial.
22 Oct (reported 23 Oct)
Moderna and Merck reported that their personalized mRNA vaccine, intismeran, reduced the risk of melanoma recurrence or death by 42% in a phase III clinical trial.
22 Oct (reported 23 Oct)
Warhound, a startup co-founded by Ben Lamm and supported by Palmer Luckey, emerged from stealth on October 22, 2026, with $200 million in funding.
22 Oct
Warhound, a startup co-founded by Ben Lamm and supported by Palmer Luckey, emerged from stealth on October 22, 2026, with $200 million in funding.
22 Oct
Warhound, a startup co-founded by Ben Lamm and supported by Palmer Luckey, emerged from stealth on October 22, 2026, with $200 million in funding.
22 Oct
The U.S. Food and Drug Administration (FDA) approved GSK's drug Hibsago (bepirovirsen) on October 20, 2026, for the treatment of adults with chronic hepatitis B who are already on nucleoside analogue therapy.
20 Oct (reported 21 Oct)
The U.S. Food and Drug Administration (FDA) approved GSK's drug Hibsago (bepirovirsen) on October 20, 2026, for the treatment of adults with chronic hepatitis B who are already on nucleoside analogue therapy.
20 Oct (reported 21 Oct)
The U.S. Food and Drug Administration (FDA) approved GSK's drug Hibsago (bepirovirsen) on October 20, 2026, for the treatment of adults with chronic hepatitis B who are already on nucleoside analogue therapy.
20 Oct (reported 21 Oct)
The U.S. Food and Drug Administration (FDA) approved GSK's drug Hibsago (bepirovirsen) on October 20, 2026, for the treatment of adults with chronic hepatitis B who are already on nucleoside analogue therapy.
20 Oct (reported 21 Oct)
Gilead Sciences has entered into a licensing agreement with PepStar Therapeutics and Shanghai Peptidstar Therapeutics to acquire global rights for an oral IL-23R inhibitor program, including the lead asset HCXT-2001.
23 Oct
President Donald Trump signed an executive order on October 19, 2026, to establish a new Women’s Health Division at the National Institutes of Health (NIH) and a White House Women’s Health Task Force.
19 Oct
Hansoh Pharmaceutical Group Co., Ltd. has entered into a strategic collaboration and license agreement with Roche to develop a portfolio of antibody-drug conjugate (ADC) programs.
19 Oct
Hansoh Pharmaceutical Group Co., Ltd. has entered into a strategic collaboration and license agreement with Roche to develop a portfolio of antibody-drug conjugate (ADC) programs.
19 Oct
Hansoh Pharmaceutical Group Co., Ltd. has entered into a strategic collaboration and license agreement with Roche to develop a portfolio of antibody-drug conjugate (ADC) programs.
19 Oct
Gilead Sciences has agreed to acquire the oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics for $1.275 billion in upfront cash.
23 Oct
Gilead Sciences has agreed to acquire the oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics for $1.275 billion in upfront cash.
23 Oct
Gilead Sciences has agreed to acquire the oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics for $1.275 billion in upfront cash.
23 Oct
Alcon has announced the acquisition of Neurotech Pharmaceuticals for $550 million to expand its cell therapy portfolio.
20 Oct (reported 22 Oct)
Alcon has announced the acquisition of Neurotech Pharmaceuticals for $550 million to expand its cell therapy portfolio.
20 Oct (reported 22 Oct)
Alcon has announced the acquisition of Neurotech Pharmaceuticals for $550 million to expand its cell therapy portfolio.
20 Oct (reported 22 Oct)
Moderna and Merck reported that their experimental cancer vaccine combined with Keytruda reduced the risk of relapse or death by 42% in a melanoma study.
22 Oct
Warp Sciences, a startup founded by former OpenAI product chief Kevin Weil, has emerged from stealth mode.
22 Oct
Warp Sciences, a startup founded by former OpenAI product chief Kevin Weil, has emerged from stealth mode.
22 Oct
The FDA has granted accelerated approval to GSK's immunotherapy drug Jemperli (dostarlimab) for the treatment of locally advanced stage II or III rectal cancer in adults with MSI-H or dMMR genetic markers.
19 Oct (reported 20 Oct)
The FDA has granted accelerated approval to GSK's immunotherapy drug Jemperli (dostarlimab) for the treatment of locally advanced stage II or III rectal cancer in adults with MSI-H or dMMR genetic markers.
19 Oct (reported 20 Oct)
The FDA has granted accelerated approval to GSK's immunotherapy drug Jemperli (dostarlimab) for the treatment of locally advanced stage II or III rectal cancer in adults with MSI-H or dMMR genetic markers.
19 Oct (reported 20 Oct)
Roche and Hansoh Pharmaceutical Group have entered into a new strategic collaboration to develop multiple antibody-drug conjugates (ADCs) for various cancer types.
19 Oct (reported 20 Oct)
Roche and Hansoh Pharmaceutical Group have entered into a new strategic collaboration to develop multiple antibody-drug conjugates (ADCs) for various cancer types.
19 Oct (reported 20 Oct)
The US FDA granted accelerated approval to GSK's Jemperli (dostarlimab-gxly) for the treatment of adults with stage II and III MSI-H/dMMR locally advanced rectal cancer.
19 Oct
The US FDA granted accelerated approval to GSK's Jemperli (dostarlimab-gxly) for the treatment of adults with stage II and III MSI-H/dMMR locally advanced rectal cancer.
19 Oct
Fractyl Health announced positive six-month results from its REMAIN-1 clinical trial for the Revita weight maintenance procedure in the United States.
16 Oct (reported 25 Oct)
Fractyl Health announced positive six-month results from its REMAIN-1 clinical trial for the Revita weight maintenance procedure in the United States.
16 Oct (reported 25 Oct)
Fractyl Health announced positive six-month results from its REMAIN-1 clinical trial for the Revita weight maintenance procedure in the United States.
16 Oct (reported 25 Oct)
Fractyl Health announced positive six-month results from its REMAIN-1 clinical trial for the Revita weight maintenance procedure in the United States.
16 Oct (reported 25 Oct)
Merck and Moderna reported Phase 3 clinical trial results for their personalized mRNA-based melanoma vaccine, Intismeran Autogene.
24 Oct
Merck and Moderna reported Phase 3 clinical trial results for their personalized mRNA-based melanoma vaccine, Intismeran Autogene.
24 Oct
Merck and Moderna reported Phase 3 clinical trial results for their personalized mRNA-based melanoma vaccine, Intismeran Autogene.
24 Oct
Merck and Moderna reported Phase 3 clinical trial results for their personalized mRNA-based melanoma vaccine, Intismeran Autogene.
24 Oct
Gilead Sciences has agreed to acquire the oral IL-23R inhibitor program, including lead candidate HCXT-2001, from the Chinese biotech company PepStar Therapeutics.
22 Oct (reported 24 Oct)
Gilead Sciences has agreed to acquire the oral IL-23R inhibitor program, including lead candidate HCXT-2001, from the Chinese biotech company PepStar Therapeutics.
22 Oct (reported 24 Oct)
At the ESMO 2026 congress in Madrid, interim Phase III data from the DeLLphi-305 study were presented on October 24, 2026.
24 Oct
Quest Diagnostics confirmed a cyberattack on its Quanum lab testing platform, which resulted in unauthorized access to sensitive patient personal and health information.
21 Oct (reported 23 Oct)
Pathos, an AI-driven drug development company, announced on October 23, 2026, that it raised $237 million in a Series E funding round led by Bristol Myers Squibb.
23 Oct
Pathos, an AI-driven drug development company, announced on October 23, 2026, that it raised $237 million in a Series E funding round led by Bristol Myers Squibb.
23 Oct
The private equity firm EQT has announced the acquisition of the molecular diagnostics company Qiagen.
23 Oct
Japanese regulators have ordered a halt to the use of the drug Tavneos in new patients and are considering a full revocation of its marketing approval.
23 Oct
60 of 500 figures are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
Publishers cited most often across the events on this page.
Choose the topics and sources that matter to you. Dailyn turns them into one concise digest.
Build my digest →Dailyn’s analysis engine screens the week’s reporting for relevance, deduplicates overlapping coverage into distinct dated events, and ranks those events by significance, source corroboration and recency. The highest-ranked events form the core of the weekly briefing.
Every line is a fact taken verbatim from a single dated article, and that article is linked in the same row. Nothing on the page is written or inferred beyond the article set.
The analysis engine extracts facts, entities and figures from the week’s reporting, and the editorial synthesis is generated from that event data. Published claims remain traceable to the underlying reporting.
A new briefing is issued for every ISO week, and the key-numbers section is refreshed with it. Each page states the exact window of dates it covers.
Dailyn’s analysis engine processes everything its monitored sources published this week: it deduplicates overlapping coverage, clusters reporting into distinct dated events, extracts the companies, deals and figures involved, and ranks the results by significance, corroboration and recency.
Everything Dailyn’s monitored sources published across the seven-day window.
The engine filters out off-topic and low-quality reporting.
Articles the engine tagged with this industry inside the window.
Sector articles that reported at least one figure inside the window.
The figures this page prints, each quoted exactly as its article reported it.
Events ranked by significance, corroboration and recency.
Every line on this page is a fact taken verbatim from a single dated article, with that article linked in the same row. Nothing on this page is written or inferred beyond the article set.
Duplicate reports of the same event are collapsed to one entry; the corroborating-source count says how many outlets carried it.
Dates are publication dates. Where an article states a different date for the event itself, that date is shown first and the publication date in brackets. A date the article gives for something still to come is shown as "due".
A figure is listed exactly as the article reported it. Figures are not converted, rebased, summed or compared across articles.
Every event stays linked to the reporting it was built from.
Pick the topics and sources that matter to you. Dailyn reads them every day and sends one concise digest.